Bipolar Disorder
Genes largely responsible for bipolar disorder transmission across generations
Cross-generational bipolar disorder transmission appeared to be caused largely by genes, with rearing effects having a modest role, according to results of an extended Swedish national adoption study published in JAMA Psychiatry.
BLOG: Concussions, depression and the eyes – it’s all connected
by Michael A. Longyear, DC, DACNB, CCSP
Five new subgroups may change psychosis taxonomy
Researchers have identified psychosis subgroups that may inform ongoing efforts to redefine psychosis taxonomy using updated criteria, according to results of a longitudinal cohort study published in JAMA Psychiatry.
Top 5 psychiatry stories of January
Voice-analysis application assesses well-being of patients with serious mental illness
An interactive voice response system that uses artificial intelligence effectively monitored the well-being of patients with serious mental illness, according to study findings published in PLOS One.
Family-focused therapy reduces mood episodes in youths at risk for bipolar disorder
Children and adolescents who are at high risk for bipolar disorder achieved longer times between mood episodes after receiving family-focused therapy, according to results of a randomized clinical trial published in JAMA Psychiatry.
BMI linked to major psychiatric disorders
Findings of a genome-wide association study published in JAMA Psychiatry suggest that many overlapping genetic risk variants exist between BMI and schizophrenia, bipolar disorder and major depression.
Air pollution exposure may increase risk for depression, suicide
Higher levels of air pollution exposure may be associated with increased rates of depression and death by suicide among those exposed, according to results of a systematic review and meta-analysis published in Environmental Health Perspectives.
Having dogs as pets may decrease schizophrenia risk
Individuals who were exposed to household pet dogs during infancy and childhood may have a decreased risk for developing schizophrenia, according to study findings published in PLoS One.
Q&A: Treatment potential of ALKS 3831 for schizophrenia, bipolar I disorder
Alkermes recently announced submission of a new drug application to the FDA for its investigational schizophrenia treatment ALKS 3831, a combination of olanzapine and samidorphan, for the treatment of schizophrenia and the treatment of bipolar I disorder. If approved, the drug is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.